



Reporting Items for Practice Guidelines in
Healthcare

Right Reporting for Right
Decisions

[Home](#) > [Right Statement](#) > [Right Checklist](#)

RIGHT Checklist

RIGHT (Reporting Items for practice Guidelines in HealThcare) Checklist				
22 Sections/topics and 35 Items		Assessment	Page(s)	Note(s)
Section/topic	No./ Item			
Basic information				
Title/subtitle				
1a	Identify the report as a guideline, that is, with "guideline(s)" or "recommendation(s)" in the title.	☒ Yes ☐ No ☐ Unclear		
1b	Describe the year of publication of the guideline.	☐ Yes ☒ No ☐ Unclear		
1c	Describe the focus of the guideline, such as screening, diagnosis, treatment, management, prevention, or others.	☒ Yes ☐ No ☐ Unclear		
Executive summary				
2	Provide a summary of the recommendations contained in the guideline.	☒ Yes ☐ No ☐ Unclear		
Abbreviations and acronyms				

3	Define new or key terms, and provide a list of abbreviations and acronyms if applicable.	☒ Yes ☐ No ☐ Unclear		
Corresponding developer				
4	Identify at least 1 corresponding developer or author who can be contacted about the guideline.	☒ Yes ☐ No ☐ Unclear		
Background				
Brief description of the health problem(s)				
5	Describe the basic epidemiology of the problem, such as the prevalence/incidence, morbidity, mortality, and burden (including financial) resulting from the problem.	☒ Yes ☐ No ☐ Unclear		
Aim(s) of the guideline and specific objectives				
6	Describe the aim(s) of the guideline and specific objectives, such as improvements in health indicators (e.g., mortality and disease prevalence), quality of life, or cost savings.	☒ Yes ☐ No ☐ Unclear		
Target populations				
7a	Describe the primary population(s) that is affected by the recommendation(s) in the guideline.	☒ Yes ☐ No ☐ Unclear		
7b	Describe any subgroups that are given special consideration in the guideline.	☐ Yes ☒ No ☐ Unclear		

End users and settings

8a	Describe the intended primary users of the guideline (such as primary care providers, clinical specialists, public health practitioners, program managers, and policymakers) and other potential users of the guideline.	☒ Yes ☐ No ☐ Unclear		
8b	Describe the setting(s) for which the guideline is intended, such as primary care, low- and middle-income countries, or inpatient facilities.	☒ Yes ☐ No ☐ Unclear		

Guideline development groups

9a	Describe how all contributors to the guideline development were selected and their roles and responsibilities (e.g., steering group, guideline panel, external reviewer, systematic review team, and methodologists).	☒ Yes ☐ No ☐ Unclear		
9b	List all individuals involved in developing the guideline, including their title, role(s) and institutional affiliation(s).	☐ Yes ☒ No ☐ Unclear		

Evidence

Health care questions

10a	State the key questions that were the basis for the recommendations in PICO (population, intervention,	☒ Yes ☐ No ☐ Unclear		
-----	--	--	--	--

	comparator, and outcome) or other format as appropriate.			
10b	Indicate how the outcomes were selected and sorted.	☒ Yes ☐ No ☐ Unclear		
Systematic reviews				
11a	Indicate whether the guideline is based on new systematic reviews done specifically for this guideline or whether existing systematic reviews were used.	☐ Yes ☒ No ☐ Unclear		
11b	If the guideline developers used existing systematic reviews, reference these and describe how those reviews were identified and assessed (provide the search strategies and the selection criteria, and describe how the risk of bias was evaluated) and whether they were updated.	☒ Yes ☐ No ☐ Unclear		
Assessment of the certainty of the body of evidence				
12	Describe the approach used to assess the certainty of the body of evidence.	☐ Yes ☒ No ☐ Unclear		
Recommendations				
Recommendations				
13a	Provide clear, precise, and actionable recommendations.	☒ Yes ☐ No ☐ Unclear		
13b	Present separate recommendations for important subgroups if the evidence	☐ Yes ☒ No ☐ Unclear		

	suggests that there are important differences in factors influencing recommendations, particularly the balance of benefits and harms across subgroups.			
13c	Indicate the strength of recommendations and the certainty of the supporting evidence.	☐ Yes ☒ No ☐ Unclear		
Rationale/explanation for recommendations				
14a	Describe whether values and preferences of the target population(s) were considered in the formulation of each recommendation. If yes, describe the approaches and methods used to elicit or identify these values and preferences. If values and preferences were not considered, provide an explanation.	☐ Yes ☒ No ☐ Unclear		
14b	Describe whether cost and resource implications were considered in the formulation of recommendations. If yes, describe the specific approaches and methods used (such as cost-effectiveness analysis) and summarize the results. If resource issues were not considered, provide an explanation.	☐ Yes ☒ No ☐ Unclear		
14c	Describe other factors taken into consideration when formulating the recommendations, such as	☒ Yes ☐ No ☐ Unclear		

	equity, feasibility and acceptability.			
Evidence to decision processes				
15	Describe the processes and approaches used by the guideline development group to make decisions, particularly the formulation of recommendations (such as how consensus was defined and achieved and whether voting was used).	☒ Yes ☐ No ☐ Unclear		
Review and quality assurance				
External review				
16	Indicate whether the draft guideline underwent independent review and, if so, how this was executed and the comments considered and addressed.	☒ Yes ☐ No ☐ Unclear		
Quality assurance				
17	Indicate whether the guideline was subjected to a quality assurance process. If yes, describe the process.	☐ Yes ☒ No ☐ Unclear		
Funding, declaration and management of interests				
Funding source(s) and role(s) of the funder				
18a	Describe the specific sources of funding for all stages of guideline development.	☐ Yes ☒ No ☐ Unclear		
18b	Describe the role of funder(s) in the different stages of guideline	☐ Yes ☒ No ☐ Unclear		

	development and in the dissemination and implementation of the recommendations.			
Declaration and management of interest				
19a	Describe what types of conflicts (financial and nonfinancial) were relevant to guideline development.	☒ Yes ☐ No ☐ Unclear		
19b	Describe how conflicts of interest were evaluated and managed and how users of the guideline can access the declarations.	☒ Yes ☐ No ☐ Unclear		
Other information				
Access				
20	Describe where the guideline, its appendices, and other related documents can be accessed.	☒ Yes ☐ No ☐ Unclear		
Suggestions for further research				
21	Describe the gaps in the evidence and/or provide suggestions for future research.	☒ Yes ☐ No ☐ Unclear		
Limitations of the guideline				
22	Describe any limitations in the guideline development process (such as the development groups were not multidisciplinary or patients' values and preferences were not sought), and indicate how these limitations might have	☒ Yes ☐ No ☐ Unclear		

affected the validity of the recommendations.

Reference:

Chen Y, Yang K, Marušić A, et al. A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement[J]. Annals of Internal Medicine, 2017, 166(2):128-132. <https://doi.org/10.7326/M16-1565>

Official Website: <http://www.right-statement.org/>

Our sponsors, supporters and partners



WHO Collaborating Centre for
Guideline Implementation and
Knowledge Translation



GUIDELINE REGISTRE



Center | Lanzhou University



Cochrane
China



 兰州大学健康数据科学研究院

Copyright 2015 - 2025 RIGHT Statement. All rights reserved.